MedTrace Logo

Efficacy of Pioglitazone on Myocardial Function in Patients Undergoing Coronary Stent Implantation.

NCT00771004 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2010-07-05

No results posted yet for this study

Summary

The purpose of this study is to determine the effects of pioglitazone, once daily (QD), on heart functioning before, during and after stent implantation.

Conditions

Interventions

DRUG

Pioglitazone

Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.

DRUG

Placebo

Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.

Sponsors & Collaborators

Principal Investigators

  • Medical Adviser Clinical Research · Takeda Pharma Gmbh, Aachen (Germany)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00771004 on ClinicalTrials.gov